Exelixis, Inc. (EXEL), Monday announced data from STELLAR-303, evaluating zanzalintinib in combination with atezolizumab versus regorafenib for patients with metastatic colorectal cancer.
The combination therapy improved median overall survival to 10.9 months versus 9.4 months with regorafenib, and significantly reduced the risk of death by 20 percent in the intention-to-treat population.
The 12- and 24- month survival rate was 46 percent and 20 percent, respectively, for those receiving the combination therapy compared to 38 percent and 10 percent, respectively, for those on regorafenib.
The safety profiles of zanzalintinib in combination with atezolizumab and of regorafenib were generally consistent with previous observations.
"While treating non-MSI-high metastatic colorectal cancer remains a challenge, the combination of zanzalintinib and atezolizumab has shown consistent benefits across key subgroups of patients," said lead investigator Anwaar Saeed.
The company further shared its intention to submit its first new drug application for zanzalintinib before the year end.
In the pre-market hours, EXEL is moving down 8.28 percent, to $36 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.